Brief Introduction
Our Mission: Innovating Neurological Healthcare
Repurposing FDA-Approved Drugs
We believe in giving new life to existing drugs. Our mission includes repurposing FDA-approved medications to explore novel treatments for neurological disorders."
Read More
Maximizing Academic and Off-label Data
Utilizing a wealth of academic research and off-label usage data, we aim to uncover unexplored drug-indication fits in neurology.
Read More
Accelerated Drug Development
Our strategy involves fast-tracking drug development by leveraging available data, speeding up the journey from research to real-world application.
Read More
Utilizing Government Incentives
We strategically use government incentives and grants to fund our research, ensuring maximum return on investment and fostering innovation in drug development."
Read MoreAbout Us
Introduction: “Based in India, GreyMatter Pharma is at the forefront of repurposing drugs for neurological, sleep-related, and neuropsychiatric disorders.”
Special Interests: “Our focus extends to addressing addiction, cognitive impairment, and related behaviors through innovative pharmaceutical solutions.”
Our Pipeline
- GM2811 for Alcohol Use Disorder (AUD)
- GM2812 for Opioid Use Disorder (OUD)
- GM2813 for Gambling Disorder
- GM2814 for Mild Cognitive Impairment (MCI)
Our Innovative Research Pipeline
GM2811 - AUD
A novel approach to treating Alcohol Use Disorder, aiming to improve lives and reduce dependency.
GM2812 - OUD
Targeting Opioid Use Disorder with groundbreaking pharmaceutical therapy.
GM2813 - Gambling Disorder
Innovative solutions for combating Gambling Disorder.
GM2814 - MCI
Addressing Mild Cognitive Impairment with advanced drug repurposing strategies.”